Introduction {#S1}
============

Antimicrobial-resistant (AMR) bacterial infections have emerged as a serious problem in clinical settings worldwide. By 2050, 10 million people may die annually from AMR infections ([@B13]). Unfortunately, the launch of new antibiotics is rapidly compromised by the emergence of resistance ([@B2]). Therefore, the development of new strategies to combat AMR bacteria is urgently needed.

Recently, vaccine development has been increasingly advocated as a new solution to AMR bacteria ([@B21]; [@B10]; [@B13]), especially for those with high risk of acquired infection ([@B8]). Vaccine candidates often target capsule polysaccharides and virulent factors that are responsible for disease pathogenesis ([@B30]). Unfortunately, AMR bacteria-targeting vaccines have not been very successful until now due to the heterogeneity in the expression levels of vaccine antigens in different circulating strains of the target pathogen ([@B9]; [@B30]). Moreover, the immunity induced by single or multiple antigens, which is usually obtained both *in vitro* or *in vivo*, might be ineffective in protecting the host because the pathobiology in human infection is more complicated and remains obscure ([@B27]).

Antibiotic resistance determinants could be considered as potential vaccine candidates ([@B23]). Although there are variations in these resistance determinants in clinical isolates, this vaccination strategy might still be effective in eradicating resistant strains by means of replacing these strains which have reduced fitness with susceptible strains when vaccination coverage is high ([@B15]; [@B24]). This approach has an advantage when the resistance determinants are consistently present *in vitro* and *in vivo* and also possess less selection pressure on bacteria ([@B24]). However, this approach has not been validated yet.

The present study tested this idea in *Acinetobacter baumannii*. *A. baumannii* is considered one of the most problematic bacteria by the Infectious Disease Society of America (IDSA) ([@B4]) because of the rapid evolution of multidrug and pan-drug resistant strains. Currently, only few strains of this bacteria are still susceptible to last-line antibiotics such as, carbapenem and tigecycline (TGC) ([@B37]; [@B22]). In order to maximize the coverage of immunization, the antibiotic resistance determinants used for the vaccine candidate should be the major resistance mechanism of the antibiotic of interest in particular bacterial species. These determinants should be universal in different strains, conserved in sequence homology, and accessible by the immune system. In this aspect, carbapenem resistance determinants are not suitable vaccine candidates, as its major resistance mechanism is production of different classes of carbapenemases ([@B25]), which are very diverse in their protein sequences and structures. On the contrary, the major mechanism for TGC resistance is overexpression of efflux pumps ([@B35]). These are universal and are conserved in *A. baumannii* strains ([@B3]), and therefore, might be good vaccine candidates to test this immunization approach. The present study utilized bioinformatics tools to identify conserved and surface-exposed antigens of the chromosomal-encoded resistome of *A. baumannii*. Several protein components of the resistance-nodulation-division (RND) efflux system were identified, which have been associated with TGC resistance in *A. baumannii*. We propose an immunization approach using TGC resistance determinants in a murine pneumonia model to combat multidrug-resistant *A. baumannii*.

Materials And Methods {#S2}
=====================

Bioinformatic Tools {#S2.SS1}
-------------------

Microbial Genome Database (MBGD) was used for comparative analysis of completely sequenced microbial genomes to identify core genes that are universal from 15 *A. baumannii* genomes ([Supplementary Table S1](#DS1){ref-type="supplementary-material"}; [@B38]). PSORTb 3.0.2 ([@B40]), CELLO2GO ([@B39]), or SOSUI-GramN ([@B12]) were applied to predict the conserved residues and sub-cellular localization of these proteins. Comprehensive Antibiotic Resistance Database (CARD) was used to predict the resistome from raw genome sequence using Resistance Gene Identifier (RGI) software ([@B14]).

Bacterial Strain Preparation {#S2.SS2}
----------------------------

*A. baumannii* ATCC17978 reference strain was purchased from the American Type Culture Collection (ATCC). TGC-resistant clinical *A. baumannii* isolates were obtained from Tri-Service General Hospital in Taiwan ([@B36]). All isolates were identified using conventional biochemical and genomic methods as previously described ([@B36]).

Construction and Purification of Antigens {#S2.SS3}
-----------------------------------------

Recombinant AdeA (A1S_1751), *Ade*I (A1S_2735), AdeK (A1S_2737), and TolC (A1S_0255) from ATCC17978 were amplified (the primers are listed in [Supplementary Table S2](#DS1){ref-type="supplementary-material"}) and cloned into a pET-29a expression vector (Vovagen, Darmstadt, Germany) with a 6× polyhistidine tag fused to the C-terminus of the recombinant protein. The resulting plasmids were expressed and purified as described in our previous study ([@B5]). Purified proteins were digested with trypsin for subsequent liquid chromatography--mass spectrometry/mass spectrometry (LC-MS/MS) analysis and protein identification was conducted by Mission Biotech Co., Ltd., Taiwan. Sequence similarity comparison of *adeA*, *adeI*, *adeK*, and *tolC* from ATCC17978 and all isolates were analyzed using MEGA7 ([@B16]).

Mouse Immunogenicity Assessment and Pneumonia Models {#S2.SS4}
----------------------------------------------------

All animal studies were approved by the National Defense Medical Center Institutional Animal Care and Use Committee (NDMC IACUC-17-206). Female C57BL/6 mice (6 weeks old) were bred in a barrier facility under specific pathogen-free conditions. C57BL/6 mice (*n* = 10/group) were subcutaneously (sc.) immunized with 10 μg of individual recombinant antigens formulated with Complete Freund's Adjuvant/Incomplete Freund's Adjuvant (CFA/IFA) (Invivogen, Hong Kong), on days 0, 14, and 28. Blood samples were collected before the last immunization and tested against each immunogen. Immunoglobulin G (IgG) antibody titers were determined using antigen-specific enzyme-linked immunosorbent assays (ELISAs).

For conducting efficacy studies, immunized mice were challenged intra-tracheally (IT) on day 42 with a lethal dose \[3 × 10^7^ colony-forming units (CFUs)\] of mid-log phase AB247 strain mixed with 10% porcine mucin (Sigma-Aldrich, MO, United States). The use of porcine mucin is to enhance the infectivity of *A. baumannii* ([@B21]). TGC (10 mg/kg/d, q12h., sc.) treatment regimen was adopted from that used in a previous study ([@B28]). After 24 h therapy, the blood, lung, spleen, and kidney were homogenized and plated to evaluate for the CFUs. For histological analysis, the excised lungs were placed in vials containing 4% formaldehyde. The lungs were placed under vacuum overnight, paraffin-embedded, and stained with hematoxylin and eosin (HE). Histological scores were assigned by independent pathologists by evaluating 3--5 fields, according to the following criteria ([@B26]): 0, no pathology; 1, minimal infiltrates of neutrophils in alveolar spaces; 2, low numbers of neutrophils in alveoli; 3, moderate numbers of neutrophils and hemorrhage in alveoli with occasional lobar involvement and focal necrosis of alveolar-wall neutrophils in bronchioles; 4, marked numbers of neutrophils, consolidation, and widespread alveolar necrosis.

Flow Cytometry {#S2.SS5}
--------------

ATCC17978 and clinical isolates from late-log-phase growth (OD~600~ ≈ 1.8) in Luria-Bertani (LB) cultures were diluted in PBS containing 0.5% (w/v) bovine serum albumin (BSA) as a blocking buffer to an OD~600~ of 0.03. Each specific antiserum was added at a 1:100 dilution with the bacterium. Unbound antibody was removed by washing twice, then fixed by incubating with 4% formaldehyde/PBS for 10 min on ice. A secondary antibody, goat anti-mouse IgG-PE (Invitrogen Corp., Carlsbad, CA, United States) at 0.1 mL per well, was added at a 1:100 dilution and incubated for 30 min. The bacteria were analyzed using a FACSCalibur flow cytometer (BD, Franklin Lakes, NJ, United States). Wash buffer, secondary antibody, or PBS Immunize serum were used as negative controls.

Hoechst 33342 (H33342) Accumulation Assay {#S2.SS6}
-----------------------------------------

H33342 accumulation assays were carried out as described by [@B31]. Strains were grown to an OD~600~ of 0.4 and resuspended in PBS at room temperature, and the suspension was adjusted to an OD~600~ of 0.1. Centrifugation steps were carried out at 2500 g. The wells of a black microtiter plate (Corning, Amsterdam, Netherlands) were inoculated with 176 μL of bacterial suspension and 20 μL of 10 μg/mL H33342. After 5 min equilibration, 4 μL of the efflux pump inhibitor, phenylalanine-arginine-β-naphthylamide (PAβN), or specific antisera were added. The fluorescence intensity was recorded every 1 min for 60 min on a SPECTRAmax5 fluorometer (Molecular Devices, Sunnyvale, CA, United States) at excitation and emission wavelengths of 355 and 460 nm, respectively.

Complement and Opsonophagocytosis Bactericidal Assays {#S2.SS7}
-----------------------------------------------------

ATCC17978 was freshly grown to a final bacterial cell concentration of 10^6^ CFU/mL, and aliquoted into 96 well microtiter plates (10 μL, 10^4^ cells/well). For complementary studies, 10 μL heat-inactivated or immune sera were mixed with 80 μL of undiluted human complement and added to the wells for 1 h at 37°C. The samples were plated for bacterial enumeration. Bacteriolysis activity was defined as \[1 − (CFU immune sera at 60 min/CFU of PBS-immunized antisera at 60 min)\] × 100.

For the opsonophagocytic kill assay, RAW 264.7 macrophages were cultured in RPMI 1640 (Irvine Scientific, Santa Ana, CA, United States) with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, and glutamine (Gemini BioProducts), and 50 μM β-mercaptoethanol (Sigma-Aldrich, St. Louis, MO, United States). RAW 264.7 cells were stimulated with 100 nM PMA (Sigma-Aldrich) for 3 days. RAW 264.7 macrophages (2 × 10^5^/well) and ATCC17978 (1 × 10^4^CFU/well) were added into the wells along with the heat-inactivated or immune sera (5%). After a 1 h incubation with gentle shaking, the samples were serially diluted and plated. Serum killing rates were counted by comparing the number of reduced CFUs with those observed using PBS-immunized antisera.

RNA Isolation and Quantitative Reverse Transcriptase -- PCR {#S2.SS8}
-----------------------------------------------------------

The expression level of *adeA*, *adeI*, *adeK*, and *tolC* were measured by quantitative real-time polymerase chain reaction (PCR) assays as described previously ([@B33]). The mRNA expression of *rpoB* from ATCC17978 was used for normalization with specific primers ([Supplementary Table S2](#DS1){ref-type="supplementary-material"}). The relative gene expression was expressed as fold-change calculated by the ΔΔCt method. Gene expression levels ≥ 2-fold compared to that for the reference strain, ATCC17978, were considered significant overexpression. Each experiment was performed in duplicates and at least twice independently.

Minimal Inhibitory Concentration (MIC) Determination by Broth Microdilution Method {#S2.SS9}
----------------------------------------------------------------------------------

The MICs of TGC were determined by broth microdilution methods in Mueller Hilton broth and interpreted according to the Clinical and Laboratory Standards Institute guidelines ([@B6]). Since MIC breakpoints are not established for TGC in *Acinetobacter* spp., we used the Food and Drug Administration breakpoints set for *Enterobacteriaceae* ([@B29]). Each experiment was performed in triplicate.

Statistical Analysis {#S2.SS10}
--------------------

Statistical analyses were performed using GraphPad Prism 7 software. All graphical values were represented as means ± standard error of the mean (SEM). Tests of statistical significance were performed using one-way analysis of variance and Kruskal--Wallis tests with *post hoc* analysis. Differences were considered significant for *p* \< 0.05.

Results {#S3}
=======

*In silico* Screening of Conserved Outer Membrane Efflux Pump Proteins and Generation of Recombinant Proteins {#S3.SS1}
-------------------------------------------------------------------------------------------------------------

Fifteen *A. baumannii* genomes included 12 multidrug resistant strains were used for analysis. The antibiotic susceptibility profiles of these isolates are listed in [Supplementary Table S1](#DS1){ref-type="supplementary-material"}. These strains were grouped by multilocus sequence typing (MLST) ([@B17]) and three strains belonged to international clone I (IC I), eight to IC II, three to IC III, and the last strain was unclassified, indicating a wide coverage of *A. baumannii* strains ([Figure 1A](#F1){ref-type="fig"}). A total of 2728 core genes were identified; among them, 462 non-redundant proteins were predicted to be outer membrane or extracellular proteins. CARD predicted that among the 462 conserved and surface-exposed proteins, four were associated with antibiotic resistance, including AdeA (A1S_1751), *Ade*I (A1S_2735), AdeK (A1S_2737), and TolC (A1S_0255) and were selected as vaccine candidates ([Figure 1B](#F1){ref-type="fig"}). All the proteins belonged to the chromosomally encoded RND efflux pump family and had been associated with resistance to multiple antibiotics, including TGC ([@B37]). The four recombinant proteins were expressed and purified ([Figure 1C](#F1){ref-type="fig"}). The proteins were identified and confirmed by immunoblotting ([Figure 1D](#F1){ref-type="fig"}) and LC-MS/MS analysis ([Table 1](#T1){ref-type="table"}).

![A rational strategy for potential antigen identification and verification from *A. baumannii* genomes. **(A)** The phylogenetic lineage of 15 completely sequenced *A. baumannii* strains analyzed in this study was constructed by the neighbor-joining method performed in MEGA7. Homology core genes were analyzed using the web-based MBGD tool. **(B)** Bioinformatics tools including PSORTb 3.0.2, CELLO2GO, and SOSUI-GramN were utilized to identify 462 non-redundant outer membrane or extracellular proteins from 2728 core genes. Four antimicrobial-resistant genes associated with efflux pumps were identified in the 462-protein datasets based on Comprehensive Antibiotic Resistance Database (CARD) analysis. OMP, outer membrane protein; EC, extracellular protein. **(C)** Purified proteins were analyzed by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Lane M-standard protein markers, Lane 1-purified rAdeI protein, Lane 2-purified rTolC protein, Lane 3-purified rAdeK, Lane 4-purified rAdeA protein. **(D)** Western blot analysis of purified recombinant proteins using mouse anti-His antibody. The arrow indicates dimerization of rAdeA (confirmed by LC-MS/MS).](fmicb-11-00536-g001){#F1}

###### 

Confirmation of the purified recombinant proteins by liquid chromatography--mass spectrometry/mass spectrometry (LC-MS/MS).

  **Sample name**   **Protein name**                                                                          **Accession number**          **pI**   **MW (KDa)**   **Sequence coverage**
  ----------------- ----------------------------------------------------------------------------------------- ----------------------------- -------- -------------- -----------------------
  AdeA              Multidrug RND transporter \[*A. baumannii*\]                                              gi\| [500174963](500174963)   5.46     15.714         76%
  AdeI              Multidrug RND transporter \[*A. baumannii*\]                                              gi\| [500185983](500185983)   9.04     39.778         83%
  AdeK              adeC/adeK/oprM family multidrug efflux complex outer membrane factor \[*A. baumannii*\]   gi\| [691007736](691007736)   9.12     52.770         83%
  TolC              RND transporter \[*A. baumannii*\]                                                        gi\| [500183799](500183799)   9.21     44.273         78%

Polyclonal Antibody Production and Functional Analysis {#S3.SS2}
------------------------------------------------------

We then produced antigen-specific polyclonal antibodies from C57BL/6 mice using immunization ([Figure 2A](#F2){ref-type="fig"}). All recombinant antigens (rTolC, rAdeK, rAdeI, rAdeA) formulated with CFA/IFA induced strong antigen-specific IgG antibody responses (IgG titers \> 10^5^, [Figure 2B](#F2){ref-type="fig"}) on day 42 after immunization. The results indicated that all four antigens are highly immunogenic. Antigen-specific antisera were used to verify the location of these proteins in the outer surface of bacteria by flow cytometry ([Figure 2C](#F2){ref-type="fig"}). Data confirmed that all the antisera could bind on the surface of ATCC17978, with significantly higher intensities than that for the PBS control antisera ([Figure 2D](#F2){ref-type="fig"}). *In vitro* complement-dependent and opsonophagocytosis bactericidal assays were used to assess the potential bacteria-killing activity of each antiserum. The results showed that 2--79% of ATCC17978 were inhibited by these antisera ([Figures 2E,F](#F2){ref-type="fig"}). Among them, rTolC-specific antisera had the highest killing efficacy compared to the sera from PBS-immunized mice.

![Polyclonal mouse antisera production and characterization. **(A)** Groups of C57BL/6 mice (*n* = 10) were subcutaneously immunized with either 10 μg of individual antigen (rAdeI, rTolC, rAdeK, and rAdeA) or phosphate-buffered saline (PBS) formulated with Complete Freund's Adjuvant/Incomplete Freund's Adjuvant (CFA/IFA) on days 0, 14, and 28. Blood samples were collected before sacrifice and tested against each antigen. **(B)** Serum IgG antibody titers against each antigen as indicated by enzyme-linked immunosorbent assay. **(C)** Flow cytometry (FACS) analysis demonstrating the surface accessibility of the antigen-specific antisera. Cells from late-log-phase cultures were probed with a control non-specific antibody (shaded histograms) or individual antisera (unshaded histograms). Each histogram shows the fluorescence intensity distribution of \>20,000 flow cytometry events. **(D)** Histogram representing quantitative analysis of the binding intensity from FACS studies. Bars indicate the means of at least three independent experiments ± SEM. \*\*\**p* \< 0.001. **(E)** Bacteria inhibition by each antigen-specific mouse antisera at 1:10 dilution, used in the presence of human complement and ATCC17978. **(F)** The complement-dependent opsonophagocytosis assays were performed with mouse antisera (1:10), ATCC17978 and RAW 264.7 macrophages. The results represent the percentage of bacterial survival in the assay after 1 h of incubation at 37°C compared to that in phosphate-buffered saline (PBS)-Immunized antisera. Bars indicate the means of at least three independent experiments ± SEM. ns., non-significance. \*\**p* \< 0.01, Heat, complement replaced with a heat-inactivated complement.](fmicb-11-00536-g002){#F2}

The accumulation of bis-benzamide H33342 dye provides a reliable method to evaluate the effect of agents that can block efflux pumps ([@B31]). The fold-change of fluorescence intensity dramatically increased after adding PAβN and specific antisera, except for the PBS antisera control ([Figure 3A](#F3){ref-type="fig"}, *p* \< 0.001). Notably, fluorescence intensities were slightly decreased after 40 min of antisera treatment.

![The function of efflux pump inhibition activity of each antiserum. **(A)** Fold changed-H33342 fluorescence values for ATCC17978 following growth in specific antisera and treatment with phenylalanine-arginine beta-naphthylamide (PAβN) (10 μg/mL). Mock-treated cells are also shown (gray line). The assays were performed in triplicates and the error bars show the SEM at 1-min intervals. **(B)** Minimum inhibitory concentration (MIC) of tigecycline-resistant (TGC-R) *A. baumannii* clinical isolates (*n* = 15) compared to original or specific antisera \[phosphate-buffered saline (PBS), rAdeA, rAdeI, rAdeK, and rTolC\] co-administrated by broth microdilution method. The experiments were performed in triplicates. The *p*-value was determined by Kruskal--Wallis test with Dunn's multiple comparison analysis. \*\**p* \< 0.01. **(C)** Histogram representing quantitative analysis of the binding intensity between anti-AdeK antisera and isolates from the FACS study. The bars indicate the means of at least three independent experiments ± SEM. \*\*\**p* \< 0.001.](fmicb-11-00536-g003){#F3}

To examine the synergistic effect of antisera in the MICs range for TGCs in *A. baumannii*, 15 clinical TGC-R *A. baumannii* isolates were tested ([Table 2](#T2){ref-type="table"}). The TGC MICs of all isolates were \> 4 mg/L. The sequence similarities of *adeA*, *adeI*, *adeK*, and *tolC* were determined ([Table 3](#T3){ref-type="table"}) and the similarities were very high among the isolates (98.2--100%), compared to the ATCC17978 sequence. The quantitative expression levels of *adeA, adeI, adeK*, and *tolC* were also determined. In general, all strains showed more than one pump overexpression phenotype. TGC MICs were significantly reduced after a combination with rAdeK antisera was used ([Figure 3B](#F3){ref-type="fig"}), and five of the tested isolates (AB099, AB247, AB294, AB304, AB347) revealed more than fourfold reduction in TGC MICs ([Table 2](#T2){ref-type="table"}), and all five strains had *adeA* overexpression, and similarities in *adeA* sequences was 100% in 4 of the isolates. The similarity in *adeA* sequence of AB099 was 99.8%, with only a single amino-acid substitution (N295T). However, no significant differences were found among the responses of strains to anti-rAdeK antisera regarding their sequence homology ([Table 3](#T3){ref-type="table"}), gene expression level ([Table 2](#T2){ref-type="table"}) and binding ability of antisera to bacterial cells ([Figure 3C](#F3){ref-type="fig"}). Furthermore, we examined the synergistic effect of anti-AdeK serum and four antibiotics including amikacin, meropenem, colistin and ampicillin/sulbactam, remained active against different portions of *A. baumannii* isolates. We found that only two isolates demonstrated a twofold reduction in the ampicillin-sulbactam MIC value from 64/32 to 32/16 μg/mL in the presence of anti-AdeK ([Supplementary Table S3](#DS1){ref-type="supplementary-material"}).

###### 

Minimum inhibitory concentrations (MICs) of clinical isolates and synergistic effects of antigen-specific antisera on tigecycline (TGC) MICs^a^.

  **Strains**   **Original**   **rAdeA**   **rAdeI**   **rAdeK**   **rTolC**                       
  ------------- -------------- ----------- ----------- ----------- ----------- ----- ------- ----- -------
  AB099         8              \+          8           \+          4           \+    **2**   \+    4
  AB113         16             \+          16          \+          16          \+    8       \+    16
  AB118         8              \+          8           \+          16          *−*   4       *−*   8
  AB247         16             \+          16          \+          **4**       \+    **2**   *−*   8
  AB263         16             \+          16          \+          16          \+    8       *−*   16
  AB292         8              \+          16          \+          16          *−*   16      \+    16
  AB294         8              \+          4           \+          4           \+    **2**   *−*   8
  AB299         8              \+          16          \+          8           \+    8       *−*   16
  AB304         16             \+          8           *−*         8           \+    **4**   \+    16
  AB315         16             \+          8           \+          16          *−*   8       \+    16
  AB317         16             \+          16          \+          16          \+    8       \+    16
  AB318         16             \+          16          \+          16          \+    16      *−*   16
  AB332         16             \+          8           \+          16          *−*   8       \+    16
  AB347         16             \+          16          \+          16          \+    **4**   \+    **4**
  AB349         16             \+          16          \+          16          *−*   8       *−*   16

a

Bold font indicates a fourfold reduction in MIC value. Experiments were performed in triplicate and repeated three times, with similar results.

b

OE: overexpression, gene expression level ≥ twofold compared to that of the ATCC17978 reference strain was considered significant overexpression;

+,

Yes; −, No.

###### 

Comparisons of efflux pump protein sequence similarities to *A. baumannii* ATCC 17978.

  **Strain ID**   ***adeA***       ***adeI***   ***adeK***       ***tolC***
  --------------- ---------------- ------------ ---------------- -----------------------------------------------------------------
  AB099           100%             100%         99.80% (N295T)   99.60% (Q85H, K180T)
  AB113           99.30% (T138A)   100%         99.80% (G212L)   100%
  AB118           99.30% (T138A)   100%         100%             100%
  AB247           99.30% (T138A)   100%         100%             100%
  AB263           99.30% (T138A)   100%         99.80% (G212C)   100%
  AB292           99.30% (T138A)   100%         100%             100%
  AB294           99.30% (T138A)   100%         100%             99.60% (E219V, Y220F)
  AB299           99.30% (T138A)   100%         100%             100%
  AB304           99.30% (T138A)   100%         100%             100%
  AB315           99.30% (T138A)   100%         99.80% (L296S)   100%
  AB317           99.30% (T138A)   100%         99.80% (Q193H)   99.10% (T293I, R325G, T326S, S327Y)
  AB318           99.30% (T138A)   100%         100%             100%
  AB332           99.30% (T138A)   100%         100%             100%
  AB347           99.30% (T138A)   100%         100%             98.20% (Q163R, N193C, Q195H, Y196D, A201T, A205E, N207D, A213T)
  AB349           99.30% (T138A)   100%         100%             100%

TGC Activity Potentiation by rAdeK Immunization in a Mouse Pneumonia Model {#S3.SS3}
--------------------------------------------------------------------------

According to the *in vitro* data, rAdeK antisera showed the highest capability to potentiate the effect of TGC against TGC-R *A. baumannii*, and also had an addition role to in antibody mediated killing, so rAdeK was selected as a vaccine candidate. The protocol for murine pneumonia model is shown in [Figure 4A](#F4){ref-type="fig"}. An intratracheal challenge with a clinical isolate of AB247 was performed. AB247 was selected because of its high TGC-resistant phenotype (MIC 16 mg/L) and its significant response in broth microdilution evaluation. The results showed that TGC administration in rAdeK-immunized mice significantly reduced the bacterial load in the lungs compared to that in mice without immunization ([Figure 4B](#F4){ref-type="fig"}, *p* \< 0.001). The bacterial load was also reduced in the kidney, spleen, and blood, but without statistical significance ([Figures 4C--E](#F4){ref-type="fig"}). The histopathology of lung tissues showed that neutrophil infiltration in the peri-bronchial vasculature region was lower in rAdeK-immunization and TGC-treated mice ([Figure 5](#F5){ref-type="fig"}) compared to that in other groups. More importantly, there was no evidence of morbidity or mortality among mice during the immunization course, which suggested that rAdeK is safe and suitable for immunization.

![The efficacy of rAdeK immunization in a mouse pneumonia model. **(A)** Rational design of the animal model. Treatment was initiated 4 h after challenge against *A. baumannii* AB247 \[tigecycline (TGC) minimum inhibitory concentration of 16 μg/mL\], twice a day by subcutaneous injections. Bacterial loads were determined in different organs after the mice were sacrificed and were compared among the four groups. **(B--E)** Bacterial load in the mice lungs **(B)**, kidney **(C)**, spleen **(D)**, and blood **(E)** after 24 h TGC treatment compared among the four groups studied. The bars indicate the means ± the SEM. \*\**p* \< 0.01; \*\*\**p* \< 0.001.](fmicb-11-00536-g004){#F4}

![The histology of mouse lung sections in pneumonia model. **(A)** Hematoxylin and eosin staining of mouse lung sections obtained from each group. Images were taken at 40× by light microscopy and represented sections from three mice per group. The arrows indicate regions of peri-bronchovascular infiltration. Bars = 100 μm. **(B)** Lung inflammation was scored, the bars indicate the means of at least three samples ± SEM. \*\*\**p* \< 0.001.](fmicb-11-00536-g005){#F5}

Discussion {#S4}
==========

AMR bacterial infection have been increasing dramatically in recent decades and account for about 80% of all severe bacterial infections ([@B7]). Resistant phenotypes can arise from overexpression of intrinsic efflux activity to effectively respond to antibiotic or toxin related challenges ([@B7]). Inhibition of antimicrobial determinants, such as efflux pump inhibitors (EPIs) is a feasible approach to preserve and improve the clinical performance of antituberculosis agents and overcome crucial drug-resistance challenges ([@B34]). The use of EPIs could facilitate the revival of antibiotics and could be suitable for clinical applications. Unfortunately, no EPIs are yet available for clinical use ([@B1]). We developed an alternative vaccine strategy targeting an antibiotic efflux pump. We tested this idea in TGC-resistant *A. baumannii*. We found that immunization with the RND efflux pump outer membrane protein, AdeK, interfered with the efflux activity of bacteria and, also induced antibodies with bactericidal effects ([Figure 6](#F6){ref-type="fig"}). When co-administrated with TGC therapy, this strategy efficiently attenuated TGC-R *A. baumannii* pneumonia infection. A recent study showed that the combined treatment of anti-outer membrane vesicle serum and antibiotics could increase the intracellular aggregation of antibiotics by affecting porin function ([@B11]). The strategy significantly improved the antibiotic susceptibility of drug-resistant *A. baumannii* and strengthened the feasibility of combination therapy with vaccine and antibiotics. Accordingly, predominant resistance determinants with high homology, such as MecA, that confer resistance to methicillin in *Staphylococcus aureus* might also be good candidates for this approach.

![Schematic representation of the proposed mechanism of anti-efflux antibodies-mediated tigecycline efflux inhibition and bactericidal activity. Under overexpressed conditions, activated efflux pumps efficiently remove tigecycline to attenuate antibiotic activity **(left)**. These phenomena might be restored by using an anti-rAdeK antibody as an efflux pump inhibitor. Bactericidal effects might also be induced via complement-mediated lytic membrane attack complex pores and opsonophagocytic activity **(right)**.](fmicb-11-00536-g006){#F6}

Efflux-mediated TGC resistance has been extensively investigated in *A. baumannii*, especially in RND efflux pumps such as AdeABC, AdeFGH, AdeIJK, and AcrAB-TolC, in which overexpression leads to a TGC-resistant phenotype ([@B35]). Moreover, mutations in the *adeR* and *adeS* regulatory genes have been detected in TGC-R clinical isolates with efflux pump overexpression ([@B36]). Therefore, inhibition of efflux activity is a promising approach to restore TGC susceptibility. RND efflux systems usually comprise three different components assembling into a functional complex, including outer membrane protein, middle periplasmic protein and inner membrane protein ([@B7]). AdeA and AdeI belonged to the inner membrane protein of the system, whereas AdeK and TolC belonged to the outer membrane protein of the system. The results of kinetic accumulation study in the present study showed that all the antisera could potentially attenuate bisbenzimide H33342 efflux activity in ATCC strains, indicating H33342 is the substrate of these efflux systems. Decreased accumulation of H33342 after 40 min of antisera treatment ([Figure 3A](#F3){ref-type="fig"}) might indicate the activation of the redundant efflux system to extrude H33342. Compared to other antisera, rAdeK antisera efficiently reduced TGC MIC levels in the clinical isolates; this result might indicate the major contribution of AdeIJK in TGC resistance in *A. baumannii* ([@B33]). It is interesting that when targeting the same RND system (AdeIJK), different components of the system could have different effects. For example, antisera against AdeK could potentiate TGC effects but antisera against *Ade*I could not. This result indicated that the outer membrane component might be a better vaccine candidate than inner membrane protein when combined with antibiotic use. As demonstrated in [Figure 3C](#F3){ref-type="fig"}, antisera against rAdeK derived from ATCC17978 could cross-react with all fifteen clinical isolates by flow cytometry assay. The *in vivo* study also demonstrated a good response in AdeK-vaccinated and TGC-treated mice, as they demonstrated less lung inflammation and reduced bacterial load in the lung. The bacteria load in other tissues was also lower in the AdeK-vaccinated and TGC-treated mice, but the difference was not significant. This might be due to the lower bacterial load (about 10^3^ CFU/g) in the no treatment or single treatment arms (rAdeK vaccinated or TGC-treated group), as *A. baumannii* is a bacterium with low virulence.

In addition to the potentiation of antibiotic treatment, the antisera had other roles as it could enhance the antibody mediated killing of bacteria. In the *in vivo* study, the effect of AdeK immunization might come from two aspects, one is antagonizing the efflux pump against antibiotic extrusion, another is through antibody mediated killing. It is unknown how the antisera of the efflux pump could reverse the antibiotic resistance. It is reported that antibodies may affect the function of specific antigens via conformation changes ([@B32]), or that this effect could be a result of blocking the channel of antibiotic extrusion. Some efflux pumps are associated with bacterial virulence and biofilm formation, which are responsible for host cell adhesion and invasion ([@B7]). For example, TolC is a virulence factor associated with toxin translocation in *E. coli* ([@B19]). In our study, antisera derived from immunization with rTolC conferred significant complement-dependent bactericidal and opsonophagocytic activity. It is worth to determine whether rTolC could be an ideal vaccine candidate in future studies.

The non-responding strains also had similar *adeK* sequence and overexpression level of the gene. Unknown mechanisms for TGC resistance may have been present in the non-responding strains. [@B20] identified \> 50 possible drug efflux pumps that could contribute to multidrug resistance from over 1000 genomes of *A. baumannii* strains. In addition, the antibody might need to be optimized to more effectively block the most critical epitope of the efflux protein. Future research should focus on physical data in three-dimensional structures of efflux pumps and specific antibodies need to be elucidated to understand the structure-function relationships in these pumps ([@B32]). Although only 26.7% of strains had reduced TGC MIC after adding antisera, low coverage of the bacteria population (even 1--4%) by immunization with resistant determinants might still be effective in eradicating the resistant population ([@B24]).

We examined the effect of the anti-AdeK antisera on amikacin, meropenem, colistin, and ampicillin/sulbactam ([Supplementary Table S3](#DS1){ref-type="supplementary-material"}). These results showed no significant synergistic effect to reverse the resistance against these antibiotics. These was not unexpected, as the major resistant mechanisms of these antibiotics are not through efflux pump. Instead, the major resistance mechanism for amikacin, meropenem and ampicillin/sulbactam is the production of antibiotic modifying or degrading enzymes ([@B18]), whereas modification or loss of lipopolysaccharide confers colistin resistance in *A. baumannii*.

It is important to note that efflux pumps are conserved not only in *A. baumannii* but also in different bacterial genera. The AdeK protein has sequence homology to efflux proteins in other nosocomial "bad bugs" listed by the Infectious Diseases Society of America ([@B4]; [Supplementary Table S4](#DS1){ref-type="supplementary-material"}), thus having the potential of broader coverage and application in the near future. A recent report also supported that AdeK and other 24 resistant determinants are predicted as vaccine candidates to strengthen antibiotic treatments ([@B23]).

Conclusion {#S5}
==========

In conclusion, our results demonstrate that active immunization with antibiotic-resistant determinants may be a promising approach to combat multidrug-resistant pathogens in high-risk population.

Data Availability Statement {#S6}
===========================

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

Ethics Statement {#S7}
================

The animal study was reviewed and approved by National Defense Medical Center Institutional Animal Care and Use Committee (NDMC IACUC-17-206).

Author Contributions {#S8}
====================

M-HC, T-LC, and Y-PC contributed to the conception and design of the studies. M-HC, Y-SY, S-CK, and Y-PC contributed to the execution of the animal vaccination studies. M-HC, Y-TL, and J-RS carried out the laboratory *in vitro* assays. M-HC, Y-SY, Y-CW, S-CK, Y-TL, Y-PC, and T-LC were involved in the drafting, revision, and approval of the final version of the manuscript.

Conflict of Interest {#conf1}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This work was supported by the Ministry of Science and Technology (Grant Nos. MOST 105-2628-B-016-003-MY2, MOST 105-2314-B-016-039-MY3, MOST 107-2314-B-016-051-MY3, MOST 107-2320-B-016-003, MOST 108-2314-B-016-029, and MOST 109-2320-B-016-002-MY2), Tri-Service General Hospital (Grant Nos. TSGH-C107-098 and TSGH-C108-137). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

This study was supported by the ACTION study group. The members of the ACTION study group include Yea-Yuan Chang (National Yang-Ming University Hospital, Yilan, Taiwan), Yuag-Meng Liu (Changhua Christian Hospital, Changhua, Taiwan), S-CK (National Institute of Infectious Diseases and Vaccinology, National Health Research Institute, Miaoli County, Taiwan), Chang-Pan Liu (MacKay Memorial Hospital, Taipei, Taiwan), T-LC (Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan), Y-TL (Taipei Veterans General Hospital, Taipei, Taiwan), and Y-SY (National Defense Medical Center, Taipei, Taiwan).

Supplementary Material {#S11}
======================

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fmicb.2020.00536/full#supplementary-material>

###### 

Click here for additional data file.

[^1]: Edited by: Rustam Aminov, University of Aberdeen, United Kingdom

[^2]: Reviewed by: Maria Bagattini, University of Naples Federico II, Italy; Hua Zhou, Zhejiang University, China; Weiwei Huang, Chinese Academy of Medical Sciences and Peking Union Medical College, China

[^3]: ^†^These authors have contributed equally to this work

[^4]: This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology
